ARTV
NASDAQArtiva Biotherapeutics Inc.
Price$9.79+0.05 (+0.51%)
02:00 PM07:45 PM
News · 26 weeks53-81%
2025-12-282026-06-21
Mix3390d
- Other13(39%)
- Insider10(30%)
- SEC Filings9(27%)
- Leadership1(3%)
Latest news
25 items- PRArtiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceSAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on Tuesday, June 30, 2026, at 3:30 pm EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva’s website. The archived audio webcast will remain available for replay on Artiva’s website for 90 days. About
- INSIDERDirector Ra Capital Management, L.P. bought $4,599,903 worth of shares (531,326 units at $8.66) (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Artiva Biotherapeutics Inc.SCHEDULE 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
- INSIDERDirector Ra Capital Management, L.P. bought $7,650,148 worth of shares (1,027,722 units at $7.44) (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- PRArtiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast TodayMultiple EULAR presentations reinforce potential of AlloNK to drive deep B-cell depletion and meaningful clinical responses across refractory rheumatoid arthritis, Sjögren disease and systemic sclerosisLate-breaking oral presentation highlighted robust clinical responses with AlloNK plus rituximab across 31 patients with rheumatologic diseasesRheumatoid arthritis data showed clinically meaningful responses in highly refractory patients, including 71% ACR50 response at six months in the company-sponsored Phase 2a basket trialSafety and translational data support AlloNK's potential as an outpatient-administered, community-compatible deep B-cell depleting therapyU.S. Food and Drug Administratio
- PRThe $13 Million Company Teaching the Immune System to Hunt CancerIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /CNW/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ:GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three sep
- INSIDERLarge owner Gc Corp. bought $16,499,992 worth of shares (1,432,291 units at $11.52) (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- PRArtiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare ConferenceSAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 9:20 am EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva's website. The archived audio webcast will remain available for replay on Artiva's website for 90 days. About Arti
- INSIDERSVP, Research and Development Raymon Heather sold $27,879 worth of shares (3,095 units at $9.01), decreasing direct ownership by 2% to 148,228 units (SEC Form 4) to satisfy withholding tax4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERChief Tech Operations Officer Horan Christopher sold $63,073 worth of shares (7,002 units at $9.01), decreasing direct ownership by 2% to 293,450 units (SEC Form 4) (for withholding tax)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERCOO, CLO, Compliance Officer Bush Jennifer sold $79,179 worth of shares (8,790 units at $9.01), decreasing direct ownership by 3% to 337,920 units (SEC Form 4) (tax liability)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERChief Medical Officer Banerjee Subhashis sold $63,386 worth of shares (7,037 units at $9.01), decreasing direct ownership by 5% to 144,963 units (SEC Form 4) to cover withholding tax4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- INSIDERChief Executive Officer Aslan Fred sold $244,253 worth of shares (27,116 units at $9.01), decreasing direct ownership by 2% to 1,535,082 units (SEC Form 4) (withholding tax)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- PRArtiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic DiseasesLate-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, including 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up with no patients relapsing or requiring new immunomodulatory agentsOral presentation to feature positive experience in the first patient with severe Sjögren disease treated with AlloNK + rituximabPoster presentations to highlight deep, consistent B-cell depletion comparable to CD19 CAR T-cell therapies and a favorable safety profile in immune-mediated diseasesLive post-meeting webcast to be held Monday, June 8
- INSIDERPresident & Head of R&D Miralles Gines Diego was granted 77,500 shares (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- SECSEC Form 8-K filed by Artiva Biotherapeutics Inc.8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
- PRArtiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and DevelopmentVeteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple therapeutics from discovery through FDA approval and commercialization, including PREZISTA® and INTELENCE® SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced the appointment of Diego Miralles, M.D., as President and Head of Research and Development. Dr. Miralles brings
- SECSEC Form 144 filed by Artiva Biotherapeutics Inc.144 - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
- SECSEC Form 144 filed by Artiva Biotherapeutics Inc.144 - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
- SECSEC Form SCHEDULE 13G filed by Artiva Biotherapeutics Inc.SCHEDULE 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
- PRSolid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth PhaseMarket News Updates News Commentary Breakthrough immunotherapies, ADCs, and precision oncology platforms continue driving major investor attention across the global cancer treatment sectorNEW YORK, May 14, 2026 /CNW/ -- Momentum around solid tumor cancer treatments is picking up fast as new technologies and therapies continue delivering encouraging results across some of the hardest-to-treat cancers. From lung and breast cancer to colorectal, ovarian, and pancreatic cancers, drug developers are making real progress with next-generation immunotherapies, targeted treatments, and antibody-drug conjugates (ADCs). What's getting the industry excited is that many of these newer therapies are showi
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Artiva Biotherapeutics Inc.SCHEDULE 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)
- INSIDERDirector Ra Capital Management, L.P. bought $74,999,992 worth of shares (6,510,416 units at $11.52) (SEC Form 4)4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)
- SECSEC Form 8-K filed by Artiva Biotherapeutics Inc.8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
- SECSEC Form 424B5 filed by Artiva Biotherapeutics Inc.424B5 - Artiva Biotherapeutics, Inc. (0001817241) (Filer)
ARTV FAQ
6 questionsWhere does ARTV stock trade?
Artiva Biotherapeutics Inc. (ARTV) is listed on NASDAQ.What sector and industry is ARTV in?
Artiva Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Artiva Biotherapeutics Inc. go public?
Artiva Biotherapeutics Inc. (ARTV) completed its IPO in 2024.What are analysts saying about ARTV?
Artiva Biotherapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $1200.00 price target on 2025-06-11. Recent price targets range from $1200.00 to $2300.00.What companies are similar to ARTV?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare ARTV side-by-side with any of them on Quantisnow.How can I track ARTV on Quantisnow?
Quantisnow aggregates Artiva Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ARTV to receive live email and push alerts on every new disclosure.